Letrozol Accord

Letrozole, the active ingredient in Letrozol Accord, is an aromatase inhibitor presented as an oral tablet for systemic administration. It works by lowering estrogen levels and is indicated for the treatment of hormone receptor‑positive breast cancer in postmenopausal women, helping to slow tumor progression.

GNH USA supplies Letrozol Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide, providing reliable access to this essential antineoplastic hormone therapy through regulated distribution channels.

Letrozol Accord is an aromatase inhibitor used in the management of hormone‑dependent breast cancer.

- Adjuvant treatment of hormone receptor‑positive breast cancer: reduces risk of recurrence after surgery in postmenopausal women. - Metastatic breast cancer therapy: slows disease progression in advanced hormone‑dependent tumors. - Neoadjuvant therapy for breast cancer: shrinks tumor size before surgery in eligible patients.

Adverse reactions may occur with Letrozol Accord and should be monitored.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint and muscle pain: aches in limbs and back. - Fatigue: persistent tiredness. - Nausea: mild to moderate upset stomach. - Headache: tension or throbbing pain. - Increased sweating: excessive perspiration.

Serious or Rare Side Effects: - Severe bone loss or osteoporosis: increased fracture risk. - Liver function abnormalities: elevated enzymes. - Thromboembolic events: blood clots in veins. - Severe allergic reactions: rash, swelling, difficulty breathing. - Cardiac arrhythmias: QT interval prolongation.

Before initiating therapy, consider the following safety measures.

- Bone health assessment: evaluate risk of osteoporosis and consider calcium/vitamin D supplementation. - Liver monitoring: check hepatic enzymes periodically. - Cardiovascular review: assess history of thromboembolic disease. - Menopausal status: avoid use in premenopausal women unless ovarian suppression is confirmed. - Pregnancy and lactation: contraindicated; avoid in women of childbearing potential without effective contraception. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Letrozol Accord may interact with other medicines; awareness of the interaction level is essential.

Major Interactions (Avoid): - Tamoxifen: antagonistic effect reduces therapeutic benefit. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly lower letrozole plasma concentrations. - Estrogen‑containing hormonal therapies: diminish efficacy of aromatase inhibition.

Moderate Interactions (Monitor Closely): - SSRIs such as fluoxetine: may alter letrozole metabolism, requiring clinical observation. - Warfarin: potential effect on anticoagulation parameters; monitor INR regularly.